PMC1784092_01
Axial MRI of the left popliteal fossa showing two enlarged nodes in close proximity to the popliteal vessels.
1477-7819-5-8-1.jpg
PMC1784092_01_1477-7819-5-8-1.jpg
F1
Ultrasounds study (US) and magnetic resonance imaging (MRI) (Figure 1, 2) revealed evidence of two involved nodes in the popliteal fossa measuring respectively 2.7 x 1.7 and 2.3 x 1.5 cm, positive for metastatic melanoma by FNAC.
Sagittal MRI of the left popliteal fossa showing two involved nodes anterior to the neurovascular bundle.
1477-7819-5-8-2.jpg
PMC1784092_01_1477-7819-5-8-2.jpg
F2
Ultrasounds study (US) and magnetic resonance imaging (MRI) (Figure 1, 2) revealed evidence of two involved nodes in the popliteal fossa measuring respectively 2.7 x 1.7 and 2.3 x 1.5 cm, positive for metastatic melanoma by FNAC.
PET whole-body showing systemic uptake of the radiotracer.
1477-7819-5-8-3.jpg
PMC1784092_01_1477-7819-5-8-3.jpg
F3
In the October 2005 during follow-up control, whole body positron emission tomography (PET) showed uptake of the radiotracer in the superficial tissues of the trunk, left thigh, left leg and in the abdomino-pelvic area (Figure 3).
PET whole-body performed after chemotherapy, showing no signs of systemic disease.
1477-7819-5-8-4.jpg
PMC1784092_01_1477-7819-5-8-4.jpg
F4
After surgery he received chemotherapy (fotemustine 100 mg/m2 plus dacarbazine 900 mg/m2 intravenously, every three weeks, for a total of nine cycles) and in September 2006 the patient is alive with no evidence of disease (Figure 4, 5).
PET whole-body performed after chemotherapy, showing no evidence of disease in the left popliteal fossa.
1477-7819-5-8-5.jpg
PMC1784092_01_1477-7819-5-8-5.jpg
F5
After surgery he received chemotherapy (fotemustine 100 mg/m2 plus dacarbazine 900 mg/m2 intravenously, every three weeks, for a total of nine cycles) and in September 2006 the patient is alive with no evidence of disease (Figure 4, 5).